The emergence of drug-resistant tuberculosis in New York City.

BACKGROUND In the past decade the incidence of tuberculosis has increased nationwide and more than doubled in New York City, where there have been recent nosocomial outbreaks of multidrug-resistant tuberculosis. METHODS We collected information on every patient in New York City with a positive culture for Mycobacterium tuberculosis during April 1991. Drug-susceptibility testing was performed at the Centers for Disease Control and Prevention. RESULTS Of the 518 patients with positive cultures, 466 (90 percent) had isolates available for testing. Overall, 33 percent of these patients had isolates resistant to one or more antituberculosis drugs, 26 percent had isolates resistant to at least isoniazid, and 19 percent had isolates resistant to both isoniazid and rifampin. Of the 239 patients who had received antituberculosis therapy, 44 percent had isolates resistant to one or more drugs and 30 percent had isolates resistant to both isoniazid and rifampin. Among the patients who had never been treated, the proportion with resistance to one or more drugs increased from 10 percent in 1982 through 1984 to 23 percent in 1991 (P = 0.003). Patients who had never been treated and who were infected with the human immunodeficiency virus (HIV) or reported injection-drug use were more likely to have resistant isolates. Among patients with the acquired immunodeficiency syndrome, those with resistant isolates were more likely to die during follow-up through January 1992 (80 percent vs. 47 percent, P = 0.02). A history of antituberculosis therapy was the strongest predictor of the presence of resistant organisms (odds ratio, 2.7; P < 0.001). CONCLUSIONS There has been a marked increase in drug-resistant tuberculosis in New York City. Previously treated patients, those infected with HIV, and injection-drug users are at increased risk for drug resistance. Measures to control and prevent drug-resistant tuberculosis are urgently needed.

[1]  J. Kilburn,et al.  Identification of mycobacteria by high-performance liquid chromatography , 1991, Journal of clinical microbiology.

[2]  K. Brudney,et al.  Resurgent Tuberculosis in New York City: Human Immunodeficiency Virus, Homelessness, and the Decline of Tuberculosis Control Programs , 1991, The American review of respiratory disease.

[3]  D. Snider,et al.  Tuberculosis in patients with human immunodeficiency virus infection. , 1991, The New England journal of medicine.

[4]  S. Carbonara,et al.  Emergence of drug-resistant Mycobacterium tuberculosis in HIV-infected patients , 1991, The Lancet.

[5]  R. Shafer,et al.  HIV prevalence, immunosuppression, and drug resistance in patients with tuberculosis in an area endemic for AIDS , 1991, AIDS.

[6]  D. Snider,et al.  The epidemiology of tuberculosis in the United States. Implications for diagnosis and treatment. , 1989, Clinics in chest medicine.

[7]  L. Riley,et al.  The epidemiologic patterns of drug-resistant Mycobacterium tuberculosis infections: a community-based study. , 1989, The American review of respiratory disease.

[8]  S. Vermund,et al.  A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. , 1989, The New England journal of medicine.

[9]  I. Ben-Dov,et al.  Drug-resistant tuberculosis in a southern California hospital. Trends from 1969 to 1984. , 2015, The American review of respiratory disease.

[10]  P. Barnes The influence of epidemiologic factors on drug resistance rates in tuberculosis. , 1987, The American review of respiratory disease.

[11]  A. Haupt,et al.  Implications of emerging isoniazid resistance in Mycobacterium tuberculosis in Korea. , 1987, Aviation, space, and environmental medicine.

[12]  E. Nardell,et al.  Exogenous reinfection with tuberculosis in a shelter for the homeless. , 1986, The New England journal of medicine.

[13]  M. Goble Drug-resistant tuberculosis. , 1986, Seminars in respiratory infections.

[14]  J. Gibson Drug-resistant tuberculosis in Sierra Leone. , 1986, Tubercle.

[15]  J. Sbarbaro Strategies to improve compliance with therapy. , 1985, The American journal of medicine.

[16]  W. Addington,et al.  Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States. , 1979, Chest.

[17]  D. Shennan RESISTANCE OF TUBERCLE BACILLI TO ISONIAZID, PAS AND STREPTOMYCIN, RELATED TO HISTORY OF PREVIOUS TREATMENT. , 1964, Tubercle.